PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 32402072-15 2021 A TRANSLATIONAL PERSPECTIVE: We clearly demonstrated that febuxostat, an inhibitor of xanthine oxidase (XO), prevents exercise intolerance and skeletal muscle abnormalities (mitochondrial dysfunction and atrophy) via the suppression of XO-derived reactive oxygen species increase during hypoxia (e.g., myocardial infarction [MI]) in skeletal muscle during the early phase of heart failure (HF) model mouse. febuxostat 58-68 xanthine dehydrogenase Mus musculus 86-102 32402072-15 2021 A TRANSLATIONAL PERSPECTIVE: We clearly demonstrated that febuxostat, an inhibitor of xanthine oxidase (XO), prevents exercise intolerance and skeletal muscle abnormalities (mitochondrial dysfunction and atrophy) via the suppression of XO-derived reactive oxygen species increase during hypoxia (e.g., myocardial infarction [MI]) in skeletal muscle during the early phase of heart failure (HF) model mouse. febuxostat 58-68 xanthine dehydrogenase Mus musculus 104-106 32402072-15 2021 A TRANSLATIONAL PERSPECTIVE: We clearly demonstrated that febuxostat, an inhibitor of xanthine oxidase (XO), prevents exercise intolerance and skeletal muscle abnormalities (mitochondrial dysfunction and atrophy) via the suppression of XO-derived reactive oxygen species increase during hypoxia (e.g., myocardial infarction [MI]) in skeletal muscle during the early phase of heart failure (HF) model mouse. febuxostat 58-68 xanthine dehydrogenase Mus musculus 236-238 33681587-14 2021 Lastly, the expression of KLF6 was significantly suppressed by propofol but greatly elevated by febuxostat. febuxostat 96-106 Kruppel like factor 6 Homo sapiens 26-30 33681587-15 2021 Conclusion: Febuxostat prevented the cytotoxicity of propofol in brain endothelial cells by alleviating oxidative stress and inflammatory response through KLF6. febuxostat 12-22 Kruppel like factor 6 Homo sapiens 155-159 33634117-5 2021 We showed both in murine primary chondrocyte and chondrogenic ATDC5 cells, that mineralization was inhibited by two different XOR inhibitors, febuxostat and allopurinol. febuxostat 142-152 xanthine dehydrogenase Mus musculus 126-129 33010420-8 2021 Moreover, FEB reduced VDN-induced elevations in aortic calcium deposition, SBP and DBP. febuxostat 10-13 spermine binding protein Rattus norvegicus 75-78 33010420-8 2021 Moreover, FEB reduced VDN-induced elevations in aortic calcium deposition, SBP and DBP. febuxostat 10-13 D-box binding PAR bZIP transcription factor Rattus norvegicus 83-86 33010420-10 2021 Mechanistically, FEB dose-dependently improved oxidative damage, decreased levels of IL-1beta and Runx2, lessened expression of TNF-alpha, iNOS and MMP-9 and enhanced expression of OPN and alpha-SMA in VDN aortas relative to controls. febuxostat 17-20 interleukin 1 alpha Rattus norvegicus 85-93 33010420-10 2021 Mechanistically, FEB dose-dependently improved oxidative damage, decreased levels of IL-1beta and Runx2, lessened expression of TNF-alpha, iNOS and MMP-9 and enhanced expression of OPN and alpha-SMA in VDN aortas relative to controls. febuxostat 17-20 RUNX family transcription factor 2 Rattus norvegicus 98-103 33010420-10 2021 Mechanistically, FEB dose-dependently improved oxidative damage, decreased levels of IL-1beta and Runx2, lessened expression of TNF-alpha, iNOS and MMP-9 and enhanced expression of OPN and alpha-SMA in VDN aortas relative to controls. febuxostat 17-20 tumor necrosis factor Rattus norvegicus 128-137 33010420-10 2021 Mechanistically, FEB dose-dependently improved oxidative damage, decreased levels of IL-1beta and Runx2, lessened expression of TNF-alpha, iNOS and MMP-9 and enhanced expression of OPN and alpha-SMA in VDN aortas relative to controls. febuxostat 17-20 nitric oxide synthase 2 Rattus norvegicus 139-143 33010420-10 2021 Mechanistically, FEB dose-dependently improved oxidative damage, decreased levels of IL-1beta and Runx2, lessened expression of TNF-alpha, iNOS and MMP-9 and enhanced expression of OPN and alpha-SMA in VDN aortas relative to controls. febuxostat 17-20 matrix metallopeptidase 9 Rattus norvegicus 148-153 33010420-10 2021 Mechanistically, FEB dose-dependently improved oxidative damage, decreased levels of IL-1beta and Runx2, lessened expression of TNF-alpha, iNOS and MMP-9 and enhanced expression of OPN and alpha-SMA in VDN aortas relative to controls. febuxostat 17-20 secreted phosphoprotein 1 Rattus norvegicus 181-184 33025461-0 2021 The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration. febuxostat 19-29 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-8 33025461-8 2021 Moreover, febuxostat, as a BCRP inhibitor, could enhance nilotinib sensitivity, and combination therapy with nilotinib and febuxostat may represent a promising strategy for treatment of CML. febuxostat 10-20 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-31 33176323-6 2021 Febuxostat and allopurinol significantly suppressed VCAM-1 induced by treatment with TNF-alpha in a dose-dependent manner (p < 0.05, n = 4). febuxostat 0-10 vascular cell adhesion molecule 1 Homo sapiens 52-58 33176323-6 2021 Febuxostat and allopurinol significantly suppressed VCAM-1 induced by treatment with TNF-alpha in a dose-dependent manner (p < 0.05, n = 4). febuxostat 0-10 tumor necrosis factor Homo sapiens 85-94 33176323-8 2021 Our results suggest that TNF-alpha induces VCAM-1 production via NF-kappaB, which can be blocked by febuxostat or allopurinol. febuxostat 100-110 tumor necrosis factor Homo sapiens 25-34 33176323-8 2021 Our results suggest that TNF-alpha induces VCAM-1 production via NF-kappaB, which can be blocked by febuxostat or allopurinol. febuxostat 100-110 vascular cell adhesion molecule 1 Homo sapiens 43-49 33176323-8 2021 Our results suggest that TNF-alpha induces VCAM-1 production via NF-kappaB, which can be blocked by febuxostat or allopurinol. febuxostat 100-110 nuclear factor kappa B subunit 1 Homo sapiens 65-74 33176323-9 2021 The effect of febuxostat treatment on cardiovascular events may be associated with protection against the infiltration of lymphocytes or monocytes through VCAM-1 induction in inflamed endothelial cells such as arterial sclerosis. febuxostat 14-24 vascular cell adhesion molecule 1 Homo sapiens 155-161 32926929-0 2020 Febuxostat attenuates testosterone-induced benign prostatic hyperplasia in rats via inhibiting JAK/STAT axis. febuxostat 0-10 signal transducer and activator of transcription 3 Rattus norvegicus 99-103 33153000-0 2020 Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia. febuxostat 0-10 xanthine dehydrogenase Mus musculus 14-30 33153000-11 2020 Our results indicate that febuxostat stabilized atherosclerotic plaque via suppressing the activities of macrophage MMP-9 and -13. febuxostat 26-36 matrix metallopeptidase 9 Mus musculus 116-129 32453913-8 2020 In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing membrane vesicles with a half-maximal inhibitory concentration of 0.35 microM, whereas allopurinol showed no inhibition with concentrations up to 200 microM. febuxostat 10-20 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-81 32453913-9 2020 Taken together, the results suggest that febuxostat increases rosuvastatin exposure by inhibiting its BCRP-mediated efflux in the small intestine. febuxostat 41-51 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 102-106 32453913-11 2020 Moreover, concomitant use of febuxostat may increase the exposure to BCRP substrate drugs and, thus, the risk of dose-dependent adverse effects. febuxostat 29-39 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 69-73 32841665-0 2020 Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1beta, TNF-alpha, neutrophil infiltration, and apoptosis in mice. febuxostat 0-10 chemokine (C-C motif) ligand 2 Mus musculus 81-86 32841665-0 2020 Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1beta, TNF-alpha, neutrophil infiltration, and apoptosis in mice. febuxostat 0-10 interleukin 1 alpha Mus musculus 88-96 32841665-0 2020 Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1beta, TNF-alpha, neutrophil infiltration, and apoptosis in mice. febuxostat 0-10 tumor necrosis factor Mus musculus 98-107 32926929-9 2020 Additionally, febuxostat ameliorated testosterone-induced histopathological changes, prevented the rise in cyclin D1 expression and enhanced Bax/Bcl2 ratio. febuxostat 14-24 cyclin D1 Rattus norvegicus 107-116 32926929-9 2020 Additionally, febuxostat ameliorated testosterone-induced histopathological changes, prevented the rise in cyclin D1 expression and enhanced Bax/Bcl2 ratio. febuxostat 14-24 BCL2 associated X, apoptosis regulator Rattus norvegicus 141-144 32926929-9 2020 Additionally, febuxostat ameliorated testosterone-induced histopathological changes, prevented the rise in cyclin D1 expression and enhanced Bax/Bcl2 ratio. febuxostat 14-24 BCL2, apoptosis regulator Rattus norvegicus 145-149 32706153-0 2020 Febuxostat inhibited axillary osmidrosis risk factor ATP-binding cassette transporter C11 in vitro. febuxostat 0-10 ATP binding cassette subfamily A member 4 Homo sapiens 53-85 32706153-0 2020 Febuxostat inhibited axillary osmidrosis risk factor ATP-binding cassette transporter C11 in vitro. febuxostat 0-10 RNA polymerase III subunit K Homo sapiens 86-89 31889141-0 2019 Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. febuxostat 12-22 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 82-114 31657461-1 2020 A potent xanthine oxidoreductase inhibitor (LS087) was recently proved to exhibit a similar hypouricemic potency to febuxostat. febuxostat 116-126 xanthine dehydrogenase Rattus norvegicus 9-32 32228192-0 2020 PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats. febuxostat 97-107 phosphatase and tensin homolog Rattus norvegicus 0-4 32228192-0 2020 PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats. febuxostat 97-107 vascular endothelial growth factor A Rattus norvegicus 10-14 22934314-6 1993 The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. febuxostat 18-28 xanthine dehydrogenase Homo sapiens 4-7 31889141-3 2019 In this study, we examined the drug-drug interaction between FBX and MTX in BCRP-expressing membrane vesicles. febuxostat 61-64 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 76-80 31889141-10 2019 These findings suggest that concomitant FBX enhances MTX-induced hepatotoxicity by inhibiting hepatic BCRP. febuxostat 40-43 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 102-106 31499267-2 2019 Febuxostat, a xanthine oxidase inhibitor has been shown to exert anti-inflammatory and antioxidant effects. febuxostat 0-10 xanthine dehydrogenase Mus musculus 14-30 31499267-7 2019 Treatment of mice with febuxostat significantly increased the levels of glutathione (GSH) and superoxide dismutase (SOD), and decreased the levels of malondialdehyde (MDA), carbonyl protein, xanthine oxidase, nitric oxide (NO) and myeloperoxidase (MPO) activity of colon tissue compared with those in the acetic acid-induced colitis group. febuxostat 23-33 xanthine dehydrogenase Mus musculus 191-207 31499267-7 2019 Treatment of mice with febuxostat significantly increased the levels of glutathione (GSH) and superoxide dismutase (SOD), and decreased the levels of malondialdehyde (MDA), carbonyl protein, xanthine oxidase, nitric oxide (NO) and myeloperoxidase (MPO) activity of colon tissue compared with those in the acetic acid-induced colitis group. febuxostat 23-33 myeloperoxidase Mus musculus 231-246 31499267-7 2019 Treatment of mice with febuxostat significantly increased the levels of glutathione (GSH) and superoxide dismutase (SOD), and decreased the levels of malondialdehyde (MDA), carbonyl protein, xanthine oxidase, nitric oxide (NO) and myeloperoxidase (MPO) activity of colon tissue compared with those in the acetic acid-induced colitis group. febuxostat 23-33 myeloperoxidase Mus musculus 248-251 31499267-9 2019 Furthermore treatment with febuxostat significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and interferon (IFN)-gamma, while increased the levels of IL-10 compared with the colitis group. febuxostat 27-37 tumor necrosis factor Mus musculus 100-133 31499267-9 2019 Furthermore treatment with febuxostat significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and interferon (IFN)-gamma, while increased the levels of IL-10 compared with the colitis group. febuxostat 27-37 interleukin 1 alpha Mus musculus 135-157 31499267-9 2019 Furthermore treatment with febuxostat significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and interferon (IFN)-gamma, while increased the levels of IL-10 compared with the colitis group. febuxostat 27-37 interleukin 6 Mus musculus 159-163 31499267-9 2019 Furthermore treatment with febuxostat significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and interferon (IFN)-gamma, while increased the levels of IL-10 compared with the colitis group. febuxostat 27-37 interferon gamma Mus musculus 168-190 31499267-9 2019 Furthermore treatment with febuxostat significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and interferon (IFN)-gamma, while increased the levels of IL-10 compared with the colitis group. febuxostat 27-37 interleukin 10 Mus musculus 222-227 31499267-10 2019 These results suggest that febuxostat is able to decrease the severity of acetic acid-induced colitis by inhibition of oxidative stress and inflammatory responses through NF-kappaB pathway. febuxostat 27-37 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 171-180 32201485-5 2019 Results: However, these new amide analogs of febuxostat proved to be either GIRK1/2 and GIRK1/4 activators (primary carboxamide congeners) or mGlu2 PAMs (secondary and tertiary amides) and not selective mGlu2/4 heterodimer PAMs. febuxostat 45-55 potassium inwardly-rectifying channel, subfamily J, member 3 Rattus norvegicus 76-83 32201485-5 2019 Results: However, these new amide analogs of febuxostat proved to be either GIRK1/2 and GIRK1/4 activators (primary carboxamide congeners) or mGlu2 PAMs (secondary and tertiary amides) and not selective mGlu2/4 heterodimer PAMs. febuxostat 45-55 potassium inwardly-rectifying channel, subfamily J, member 3 Rattus norvegicus 76-81 31480671-5 2019 Among the top 10 most probable inhibitors of TRPA1 with good blood brain barrier (BBB) permeability, desvenlafaxine, paliperidone, and febuxostat emerged as the most promising repurposable agents for treating MS. Molecular docking studies indicated that desvenlafaxine, paliperidone, and febuxostat are likely to induce allosteric TRPA1 channel inhibition. febuxostat 135-145 transient receptor potential cation channel subfamily A member 1 Homo sapiens 45-50 31480671-5 2019 Among the top 10 most probable inhibitors of TRPA1 with good blood brain barrier (BBB) permeability, desvenlafaxine, paliperidone, and febuxostat emerged as the most promising repurposable agents for treating MS. Molecular docking studies indicated that desvenlafaxine, paliperidone, and febuxostat are likely to induce allosteric TRPA1 channel inhibition. febuxostat 288-298 transient receptor potential cation channel subfamily A member 1 Homo sapiens 45-50 31368057-9 2019 RESULTS: Febuxostat significantly decreased the serum MDA and significantly increased the serum SOD, while no significant results were observed in the placebo group. febuxostat 9-19 superoxide dismutase 1 Homo sapiens 96-99 31042300-1 2019 Febuxostat is a novel nonpurine type of highly selective xanthine oxidoreductase inhibitor. febuxostat 0-10 xanthine dehydrogenase Rattus norvegicus 57-80 31438839-1 2019 BACKGROUND: Clinically applied as anti-gout drugs, xanthine oxidoreductase (XOR) inhibitors, especially the potent, selective, non-purine-analog XOR inhibitors febuxostat and topiroxostat, exert organ-protective effects. febuxostat 160-170 xanthine dehydrogenase Rattus norvegicus 51-74 31438839-1 2019 BACKGROUND: Clinically applied as anti-gout drugs, xanthine oxidoreductase (XOR) inhibitors, especially the potent, selective, non-purine-analog XOR inhibitors febuxostat and topiroxostat, exert organ-protective effects. febuxostat 160-170 xanthine dehydrogenase Rattus norvegicus 76-79 31438839-1 2019 BACKGROUND: Clinically applied as anti-gout drugs, xanthine oxidoreductase (XOR) inhibitors, especially the potent, selective, non-purine-analog XOR inhibitors febuxostat and topiroxostat, exert organ-protective effects. febuxostat 160-170 xanthine dehydrogenase Rattus norvegicus 145-148 31335677-10 2019 Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. febuxostat 49-59 epidermal growth factor receptor Homo sapiens 27-31 31308200-0 2019 Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. febuxostat 0-10 major histocompatibility complex, class I, B Homo sapiens 83-88 30726711-0 2019 Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades. febuxostat 22-32 advanced glycosylation end product-specific receptor Rattus norvegicus 91-95 30726711-0 2019 Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades. febuxostat 22-32 AKT serine/threonine kinase 1 Rattus norvegicus 101-104 30726711-9 2019 Administration of febuxostat inhibited the deleterious effects of paraquat on lung through inhibition of xanthine oxidase activity and related oxidative stress, downregulation of RAGE/PI3K/Akt pathway, and suppression of beta-catenin protein expression and its downstream inflammatory mediators. febuxostat 18-28 advanced glycosylation end product-specific receptor Rattus norvegicus 179-183 30726711-9 2019 Administration of febuxostat inhibited the deleterious effects of paraquat on lung through inhibition of xanthine oxidase activity and related oxidative stress, downregulation of RAGE/PI3K/Akt pathway, and suppression of beta-catenin protein expression and its downstream inflammatory mediators. febuxostat 18-28 AKT serine/threonine kinase 1 Rattus norvegicus 189-192 30726711-9 2019 Administration of febuxostat inhibited the deleterious effects of paraquat on lung through inhibition of xanthine oxidase activity and related oxidative stress, downregulation of RAGE/PI3K/Akt pathway, and suppression of beta-catenin protein expression and its downstream inflammatory mediators. febuxostat 18-28 catenin beta 1 Rattus norvegicus 221-233 30291473-6 2019 The eGFR in the febuxostat group showed an increase from 28.45 to 30.65 mL/min/1.73 m2 at 6 months, while in the allopurinol group, the eGFR decreased from 28.06 to 24.39 mL/min/1.73 m2. febuxostat 16-26 epidermal growth factor receptor Homo sapiens 4-8 30890942-8 2019 This essentially includes our recent findings, as we serendipitously identified febuxostat, a well-used agent for hyperuricemia as a strong ABCG2 inhibitor, that possesses some promising potentials. febuxostat 80-90 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 140-145 30291473-6 2019 The eGFR in the febuxostat group showed an increase from 28.45 to 30.65 mL/min/1.73 m2 at 6 months, while in the allopurinol group, the eGFR decreased from 28.06 to 24.39 mL/min/1.73 m2. febuxostat 16-26 CD59 molecule (CD59 blood group) Homo sapiens 75-80 30628645-0 2019 Febuxostat inhibits TGF-beta1-induced epithelial-mesenchymal transition via downregulation of USAG-1 expression in Madin-Darby canine kidney cells in vitro. febuxostat 0-10 transforming growth factor beta-1 proprotein Canis lupus familiaris 20-29 30628645-8 2019 Subsequently, the effects of febuxostat on TGF-beta1-induced EMT was investigated. febuxostat 29-39 transforming growth factor beta-1 proprotein Canis lupus familiaris 43-52 30628645-10 2019 Furthermore, pretreatment with febuxostat significantly restored the decreased expression levels of phosphorylated Smad1/5/8 induced by TGF-beta1 in MDCK cells. febuxostat 31-41 SMAD family member 1 Canis lupus familiaris 115-120 30628645-10 2019 Furthermore, pretreatment with febuxostat significantly restored the decreased expression levels of phosphorylated Smad1/5/8 induced by TGF-beta1 in MDCK cells. febuxostat 31-41 transforming growth factor beta-1 proprotein Canis lupus familiaris 136-145 30628645-11 2019 The results of the present study suggested that USAG-1 may be involved in the EMT process of MDCK cells induced by TGF-beta1, and febuxostat inhibited EMT by activating the Smad1/5/8 signaling pathway via downregulating the expression of USAG-1 in MDCK cells. febuxostat 130-140 SMAD family member 1 Canis lupus familiaris 173-180 30837873-8 2019 Similarly, beneficial effects have been seen in heart, skeletal muscle, or brain after treatment with allopurinol or febuxostat to inhibit xanthine oxidoreductase, which catalyzes hypoxanthine -> xanthine and xanthine -> urate reactions. febuxostat 117-127 xanthine dehydrogenase Homo sapiens 139-162 30351343-4 2019 FEB was administered every day during Ang II infusion. febuxostat 0-3 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 38-44 30351343-8 2019 Immunostaining showed that Ang II-induced macrophage infiltration in the aorta tended to be suppressed by FEB, and XO was mainly colocalized in macrophages, not in fibroblasts. febuxostat 106-109 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 27-33 30351343-13 2019 CONCLUSIONS: Our results suggested that FEB ameliorates Ang II-induced aortic fibrosis via suppressing macrophage-derived TGF-beta1 expression. febuxostat 40-43 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 56-62 30351343-13 2019 CONCLUSIONS: Our results suggested that FEB ameliorates Ang II-induced aortic fibrosis via suppressing macrophage-derived TGF-beta1 expression. febuxostat 40-43 transforming growth factor, beta 1 Mus musculus 122-131 29931553-1 2018 PURPOSE OF REVIEW: To review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy (ULT) may be modified to increase the response in the majority of patients with gout. febuxostat 132-142 xanthine dehydrogenase Homo sapiens 81-104 30291473-6 2019 The eGFR in the febuxostat group showed an increase from 28.45 to 30.65 mL/min/1.73 m2 at 6 months, while in the allopurinol group, the eGFR decreased from 28.06 to 24.39 mL/min/1.73 m2. febuxostat 16-26 CD59 molecule (CD59 blood group) Homo sapiens 174-179 29761242-12 2018 CONCLUSIONS: Benzbromarone and febuxostat could reduce SUA and maintain renal function in chronic kidney disease (CKD) patients with eGFR 20-60 mL/min/1.73 m2. febuxostat 31-41 CD59 molecule (CD59 blood group) Homo sapiens 147-152 30399409-11 2019 This effect was fully inhibited by the xanthine oxidase (XOR) inhibitor febuxostat, suggesting XOR-mediated generation of nitric oxide (NO) from nitrite as a mechanism explaining the responses to nitrite. febuxostat 72-82 xanthine dehydrogenase Rattus norvegicus 57-60 30399409-11 2019 This effect was fully inhibited by the xanthine oxidase (XOR) inhibitor febuxostat, suggesting XOR-mediated generation of nitric oxide (NO) from nitrite as a mechanism explaining the responses to nitrite. febuxostat 72-82 xanthine dehydrogenase Rattus norvegicus 95-98 30544662-0 2018 The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. febuxostat 31-41 xanthine dehydrogenase Mus musculus 4-20 30544662-0 2018 The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. febuxostat 31-41 immunoglobulin heavy constant alpha Mus musculus 72-75 30544662-3 2018 We thus investigated whether febuxostat, an XO inhibitor, exerts a protective effect against the development of IgA nephropathy, using gddY mice as an IgA nephropathy rodent model. febuxostat 29-39 xanthine dehydrogenase Mus musculus 44-46 30544662-3 2018 We thus investigated whether febuxostat, an XO inhibitor, exerts a protective effect against the development of IgA nephropathy, using gddY mice as an IgA nephropathy rodent model. febuxostat 29-39 immunoglobulin heavy constant alpha Mus musculus 112-115 30544662-5 2018 Elevated serum creatinine and degrees of glomerular sclerosis and fibrosis, judged by microscopic observations, were significantly milder in the febuxostat-treated than in the untreated gddY mice, while body weights and serum IgA concentrations did not differ between the two groups. febuxostat 145-155 immunoglobulin heavy constant alpha Mus musculus 226-229 29657221-6 2018 Our patient improved with liberal fluid intake, restriction of high adenine content foods, and oral xanthine dehydrogenase inhibitor febuxostat. febuxostat 133-143 xanthine dehydrogenase Homo sapiens 100-122 29921379-2 2018 The xanthine oxidase (XO) inhibitor, febuxostat, decreases free fatty acids-induced fat accumulation in HFDT-fed mice. febuxostat 37-47 xanthine dehydrogenase Mus musculus 4-20 29921379-2 2018 The xanthine oxidase (XO) inhibitor, febuxostat, decreases free fatty acids-induced fat accumulation in HFDT-fed mice. febuxostat 37-47 xanthine dehydrogenase Mus musculus 22-24 29359786-11 2018 NLRP3 expression was also significantly increased in the renal cortex of HUA rats compared with control and febuxostat-treated rats. febuxostat 108-118 NLR family, pyrin domain containing 3 Rattus norvegicus 0-5 29660667-3 2018 FEB was separated from endogenous plasma components (at hRF = 70) with ethyl acetate-methanol-water (9:2:1, v/v) mixture as mobile phase and quantified by densitometry at its lambdamax (315 nm). febuxostat 0-3 tumor protein, translationally-controlled 1 Homo sapiens 56-59 29642234-7 2018 The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated that the HLA-B*5801 screening had significant cost benefit for clinical management. febuxostat 97-107 major histocompatibility complex, class I, B Homo sapiens 127-132 29342419-5 2018 Our results show that ABCG2 transports oxypurinol, an active metabolite of allopurinol, whereas allopurinol and febuxostat, a new xanthine dehydrogenase inhibitor, are not substrates of ABCG2. febuxostat 112-122 xanthine dehydrogenase Homo sapiens 130-152 28904879-11 2017 A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity chi2 = 0.81, I2 = 0%, P = 0.02). febuxostat 98-108 nuclear receptor subfamily 3 group C member 1 Homo sapiens 159-162 29101234-7 2017 Finally, we also demonstrated that the anti-hyperuricemic effect of the XOD inhibitor febuxostat was enhanced by administering it at the time of day before hepatic XOD activity increased. febuxostat 86-96 xanthine dehydrogenase Mus musculus 72-75 29101234-7 2017 Finally, we also demonstrated that the anti-hyperuricemic effect of the XOD inhibitor febuxostat was enhanced by administering it at the time of day before hepatic XOD activity increased. febuxostat 86-96 xanthine dehydrogenase Mus musculus 164-167 28578274-6 2017 These effects were diminished when XOR was blocked using the selective inhibitor febuxostat. febuxostat 81-91 xanthine dehydrogenase Rattus norvegicus 35-38 28888756-7 2017 The levels of renal XOR, renal dysfunction, urinary L-FABP, tubulointerstitial damage, hypoxia, and oxidative stress were decreased or attenuated after treatment with topiroxostat or febuxostat compared with the adenine diet group. febuxostat 183-193 xanthine dehydrogenase Mus musculus 20-23 28888756-7 2017 The levels of renal XOR, renal dysfunction, urinary L-FABP, tubulointerstitial damage, hypoxia, and oxidative stress were decreased or attenuated after treatment with topiroxostat or febuxostat compared with the adenine diet group. febuxostat 183-193 fatty acid binding protein 1, liver Mus musculus 52-58 28888756-9 2017 In conclusion, topiroxostat and febuxostat attenuated renal damage under decreased AT1a expression in the adenine-induced renal injury model. febuxostat 32-42 angiotensin II receptor, type 1a Mus musculus 83-87 29107957-0 2017 Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. febuxostat 0-10 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 137-141 29107957-2 2017 We previously showed that febuxostat, a xanthine oxidase inhibitor, ameliorated both relapsing-remitting and secondary progressive experimental autoimmune encephalomyelitis (EAE) by preventing neurodegeneration in mice. febuxostat 26-36 xanthine dehydrogenase Mus musculus 40-56 29107957-4 2017 A DNA microarray analysis revealed that febuxostat treatment increased the CNS expression of several mitochondria-related genes in EAE mice, most notably including GOT2, which encodes glutamate oxaloacetate transaminase 2 (GOT2). febuxostat 40-50 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 164-168 29107957-4 2017 A DNA microarray analysis revealed that febuxostat treatment increased the CNS expression of several mitochondria-related genes in EAE mice, most notably including GOT2, which encodes glutamate oxaloacetate transaminase 2 (GOT2). febuxostat 40-50 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 184-221 29107957-4 2017 A DNA microarray analysis revealed that febuxostat treatment increased the CNS expression of several mitochondria-related genes in EAE mice, most notably including GOT2, which encodes glutamate oxaloacetate transaminase 2 (GOT2). febuxostat 40-50 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 223-227 29107957-6 2017 Whereas GOT2 expression was decreased in the spinal cord during the chronic progressive phase of EAE, febuxostat-treated EAE mice showed increased GOT2 expression. febuxostat 102-112 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 147-151 29107957-8 2017 The ability of febuxostat to preserve ATP production in the presence of rotenone was significantly reduced by GOT2 siRNA. febuxostat 15-25 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 110-114 29107957-9 2017 GOT2-mediated ATP synthesis may be a pivotal mechanism underlying the protective effect of febuxostat against neurodegeneration in EAE. febuxostat 91-101 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 0-4 28957559-9 2017 Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat. febuxostat 346-356 major histocompatibility complex, class I, B Homo sapiens 32-37 28904879-11 2017 A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity chi2 = 0.81, I2 = 0%, P = 0.02). febuxostat 98-108 nuclear receptor subfamily 3 group C member 1 Homo sapiens 190-193 28801519-0 2017 XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis. febuxostat 20-30 xanthine dehydrogenase Mus musculus 0-3 28801519-9 2017 Pretreatment of animals with febuxostat before exposure to LPS, or treatment 4 h after LPS, resulted in complete abrogation of XOR activity. febuxostat 29-39 xanthine dehydrogenase Mus musculus 127-130 28801519-10 2017 Inhibition of XOR with febuxostat did not prevent LPS-induced pulmonary vascular permeability at 24 h, however, it accelerated recovery of the pulmonary endothelial barrier integrity in response to LPS exposure. febuxostat 23-33 xanthine dehydrogenase Mus musculus 14-17 28801519-12 2017 Inhibition of XOR with febuxostat accelerates recovery of the pulmonary endothelial barrier and prevents LPS-induced mortality, whether given before or after exposure to LPS. febuxostat 23-33 xanthine dehydrogenase Mus musculus 14-17 28257823-13 2017 Sildenafil and/or febuxostat administration with doxorubicin caused a significant decrease in nephrotoxicity markers and inflammatory mediators, restoration of normal values of oxidative stress biomarkers and hampering the expression of renal caspase-3. febuxostat 18-28 caspase 3 Rattus norvegicus 243-252 28302902-12 2017 Among the evaluated predictors, multivariate analysis showed that only the lowest eGFR tertile was significantly associated with myopathy in febuxostat users. febuxostat 141-151 epidermal growth factor receptor Homo sapiens 82-86 28302902-15 2017 CONCLUSIONS: Patients with severely reduced eGFR had higher risk of myopathy with treatment of febuxostat. febuxostat 95-105 epidermal growth factor receptor Homo sapiens 44-48 28131654-0 2017 Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. febuxostat 86-96 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 11-38 28455534-0 2017 Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice. febuxostat 31-41 xanthine dehydrogenase Mus musculus 0-16 26035033-0 2017 Combination Therapies of Diacerein and Febuxostat Inhibit IL-1beta Responses and Improve Clinical Symptoms in Patients With Refractory Gout. febuxostat 39-49 interleukin 1 beta Homo sapiens 58-66 28460508-12 2017 Conclusion: Febuxostat treatment significantly inhibited EMT and reduced the levels of IL-6 and TGFbeta(1) in hyperuricemia rats. febuxostat 12-22 interleukin 6 Rattus norvegicus 87-91 28460508-12 2017 Conclusion: Febuxostat treatment significantly inhibited EMT and reduced the levels of IL-6 and TGFbeta(1) in hyperuricemia rats. febuxostat 12-22 transforming growth factor, beta 1 Rattus norvegicus 96-103 28247173-0 2017 Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion. febuxostat 59-69 xanthine dehydrogenase Homo sapiens 20-43 27916277-5 2017 Those who tested positive for HLA-B*5801 received febuxostat. febuxostat 50-60 major histocompatibility complex, class I, B Homo sapiens 30-35 28131654-0 2017 Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. febuxostat 86-96 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 40-43 28131654-2 2017 We investigated whether the polymorphisms of UGT1A1 and UGT1A3 played an important role in the disposition of the drug after oral administration of febuxostat tablet in Chinese subjects. febuxostat 148-158 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 45-51 28131654-2 2017 We investigated whether the polymorphisms of UGT1A1 and UGT1A3 played an important role in the disposition of the drug after oral administration of febuxostat tablet in Chinese subjects. febuxostat 148-158 UDP glucuronosyltransferase family 1 member A3 Homo sapiens 56-62 27878622-0 2017 Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. febuxostat 11-21 insulin Homo sapiens 25-32 29138678-0 2017 Febuxostat Modulates MAPK/NF-kappaBp65/TNF-alpha Signaling in Cardiac Ischemia-Reperfusion Injury. febuxostat 0-10 tumor necrosis factor Rattus norvegicus 39-48 28255339-10 2017 We would advise prophylaxis against gouty flare with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), or Cyclo-oxygenase-2 selective NSAID (COXIB) after febuxostat initiation. febuxostat 163-173 prostaglandin-endoperoxide synthase 2 Homo sapiens 115-132 29138678-10 2017 Febuxostat protects relatively better against IR injury than allopurinol by suppressing inflammation and apoptosis mediating the MAPK/NF-kappaBp65/TNF-alpha pathway. febuxostat 0-10 tumor necrosis factor Rattus norvegicus 147-156 28082903-0 2016 Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. febuxostat 18-28 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 45-50 28082903-6 2016 Moreover, febuxostat was revealed to be the most promising candidate of all the potential ABCG2 inhibitors based on its potent inhibition at clinical concentrations; the half-maximal inhibitory concentration of febuxostat was lower than its maximum plasma unbound concentrations reported. febuxostat 10-20 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 90-95 28082903-6 2016 Moreover, febuxostat was revealed to be the most promising candidate of all the potential ABCG2 inhibitors based on its potent inhibition at clinical concentrations; the half-maximal inhibitory concentration of febuxostat was lower than its maximum plasma unbound concentrations reported. febuxostat 211-221 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 90-95 28082903-7 2016 Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice. febuxostat 64-74 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 100-105 28082903-7 2016 Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice. febuxostat 64-74 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 162-167 28082903-7 2016 Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice. febuxostat 64-74 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 222-227 28082903-9 2016 Furthermore, the results of this study lead to a proposed new application of febuxostat for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted therapy, and also imply the potential risk of adverse effects by drug-drug interactions that could occur between febuxostat and ABCG2 substrate drugs. febuxostat 77-87 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 125-130 28082903-9 2016 Furthermore, the results of this study lead to a proposed new application of febuxostat for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted therapy, and also imply the potential risk of adverse effects by drug-drug interactions that could occur between febuxostat and ABCG2 substrate drugs. febuxostat 77-87 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 301-306 28082903-9 2016 Furthermore, the results of this study lead to a proposed new application of febuxostat for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted therapy, and also imply the potential risk of adverse effects by drug-drug interactions that could occur between febuxostat and ABCG2 substrate drugs. febuxostat 154-164 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 125-130 28082903-9 2016 Furthermore, the results of this study lead to a proposed new application of febuxostat for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted therapy, and also imply the potential risk of adverse effects by drug-drug interactions that could occur between febuxostat and ABCG2 substrate drugs. febuxostat 154-164 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 301-306 28082903-9 2016 Furthermore, the results of this study lead to a proposed new application of febuxostat for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted therapy, and also imply the potential risk of adverse effects by drug-drug interactions that could occur between febuxostat and ABCG2 substrate drugs. febuxostat 154-164 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 125-130 28082903-9 2016 Furthermore, the results of this study lead to a proposed new application of febuxostat for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted therapy, and also imply the potential risk of adverse effects by drug-drug interactions that could occur between febuxostat and ABCG2 substrate drugs. febuxostat 154-164 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 301-306 27641217-0 2016 The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin"s lymphoma : . febuxostat 16-26 FUS RNA binding protein Homo sapiens 107-110 27641217-4 2016 We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin"s lymphoma (NHL). febuxostat 45-55 FUS RNA binding protein Homo sapiens 109-112 27641217-4 2016 We retrospectively evaluated the efficacy of febuxostat 10 mg in prevention of hyperuricemia associated with TLS (HU-TLS) in 12 patients with non-Hodgkin"s lymphoma (NHL). febuxostat 45-55 FUS RNA binding protein Homo sapiens 114-120 27641217-7 2016 Thus, febuxostat 10 mg is effective in prevention of HU-TLS. febuxostat 6-16 FUS RNA binding protein Homo sapiens 53-59 27641217-8 2016 Future study is need to determine whether the incidence of HU-TLS change with dosage of febuxostat. febuxostat 88-98 FUS RNA binding protein Homo sapiens 59-65 27744114-13 2016 Increased uric acid levels after nitrite and diminished NO production during XOR-inhibition with febuxostat suggest that XOR is more active during nitrite-treatment of activated macrophages and plays an important role in the bioactivation of nitrite. febuxostat 97-107 xanthine dehydrogenase Mus musculus 77-80 27744114-13 2016 Increased uric acid levels after nitrite and diminished NO production during XOR-inhibition with febuxostat suggest that XOR is more active during nitrite-treatment of activated macrophages and plays an important role in the bioactivation of nitrite. febuxostat 97-107 xanthine dehydrogenase Mus musculus 121-124 27609225-8 2016 Following an acute dose of nitrate, plasma nitrite increased more in eNOS-/- compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. febuxostat 168-178 nitric oxide synthase 3, endothelial cell Mus musculus 69-73 27609225-8 2016 Following an acute dose of nitrate, plasma nitrite increased more in eNOS-/- compared with wt, and this augmented response was abolished by the selective XOR inhibitor febuxostat. febuxostat 168-178 xanthine dehydrogenase Mus musculus 154-157 27609225-9 2016 Livers from eNOS-/- displayed higher nitrite reducing capacity compared with wt, and this effect was attenuated by febuxostat. febuxostat 115-125 nitric oxide synthase 3, endothelial cell Mus musculus 12-16 27521759-11 2016 Providing functional evidence that omeprazole causes ED by XOR-mediated mechanisms, we found that febuxostat blunted the ED caused by omeprazole treatment. febuxostat 98-108 xanthine dehydrogenase Homo sapiens 59-62 27160064-6 2016 In vitro studies using liver and kidney homogenates revealed dose-dependent and sustained NO generation by NDBP, which was attenuated by the xanthine oxidase inhibitor febuxostat. febuxostat 168-178 xanthine dehydrogenase Mus musculus 141-157 27238746-8 2016 Febuxostat attenuated renal protein expression of TGF-ss, CTGF, collagen 4, mesenchymal markers (FSP1 and vimentin) and a tissue marker of OS nitrotyrosine. febuxostat 0-10 cellular communication network factor 2 Rattus norvegicus 58-62 27238746-8 2016 Febuxostat attenuated renal protein expression of TGF-ss, CTGF, collagen 4, mesenchymal markers (FSP1 and vimentin) and a tissue marker of OS nitrotyrosine. febuxostat 0-10 vimentin Rattus norvegicus 106-114 27423335-8 2016 However, current XOR-inhibitor drugs such as allopurinol and febuxostat may have significant adverse effects. febuxostat 61-71 xanthine dehydrogenase Homo sapiens 17-20 26903297-7 2016 IL-1beta expression in the HFD group was increased in accordance with the enhancement of NLRP3 or iNOS expression in the IPFP, whereas it was inhibited by FEB administration. febuxostat 155-158 interleukin 1 beta Mus musculus 0-8 26771445-0 2016 Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. febuxostat 28-38 major histocompatibility complex, class I, B Homo sapiens 56-61 26771445-9 2016 CONCLUSIONS: Febuxostat was more effective than allopurinol in reducing the serum urate levels of Han Chinese patients with gout or tophaceous gout who were HLA-B*5801 negative, without causing any serious skin reactions. febuxostat 13-23 major histocompatibility complex, class I, B Homo sapiens 157-162 26771445-10 2016 Febuxostat should be considered for treatment of Han Chinese patients with gout who are HLA-B*5801 negative. febuxostat 0-10 major histocompatibility complex, class I, B Homo sapiens 88-93 27029427-8 2016 Urinary excretion of L-FABP in both the Top-H and Top-L groups was significantly lower than in the adenine and Feb groups. febuxostat 111-114 fatty acid binding protein 1, liver Mus musculus 21-27 26942273-1 2016 Febuxostat is a non-purine, selective inhibitor of both isoforms of xanthine oxido-reductase (XOR), and a major alternative to the scarce number of urate-lowering medications available in the last decades. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 68-92 26713331-10 2016 Moreover, the elevated levels of TNF-alpha in BALF and lung tissue of LPS-treated rats were attenuated by febuxostat pretreatment. febuxostat 106-116 tumor necrosis factor Rattus norvegicus 33-42 26942273-1 2016 Febuxostat is a non-purine, selective inhibitor of both isoforms of xanthine oxido-reductase (XOR), and a major alternative to the scarce number of urate-lowering medications available in the last decades. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 94-97 26164850-5 2015 Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment. febuxostat 108-118 interleukin 6 Homo sapiens 14-32 26233732-9 2015 Mean eGFR in the febuxostat group showed a nonsignificant increase from 31.5+-13.6 (SD) to 34.7+-18.1mL/min/1.73m(2) at 6 months. febuxostat 17-27 CD59 molecule (CD59 blood group) Homo sapiens 104-109 26036690-9 2015 Febuxostat also exhibited significant anti-inflammatory (decreased expression of NF-kappaBp65, IKK-beta and TNF-alpha) and anti-apoptotic effect (increased Bcl-2 expression and decreased Bax and caspase-3 expression and TUNEL positivity). febuxostat 0-10 inhibitor of nuclear factor kappa B kinase subunit beta Rattus norvegicus 95-103 25676011-11 2015 However, treatment with febuxostat for 12 weeks reduced the urinary levels of L-FABP, albumin, and beta2MG, whereas the levels of these markers did not change in the control group. febuxostat 24-34 fatty acid binding protein 1 Homo sapiens 78-84 25676011-11 2015 However, treatment with febuxostat for 12 weeks reduced the urinary levels of L-FABP, albumin, and beta2MG, whereas the levels of these markers did not change in the control group. febuxostat 24-34 beta-2-microglobulin Homo sapiens 99-106 26482071-2 2015 We hypothesized that febuxostat, a xanthine oxidase inhibitor, may be associated with suppressing the renin-angiotensin-aldosterone system (RAAS) and improving renal function in hyperurecemic patients with hypertension. febuxostat 21-31 renin Homo sapiens 102-107 26365588-1 2015 WHAT IS KNOWN AND OBJECTIVE: Febuxostat is recommended as an alternative drug for gouty patients with a history of allopurinol hypersensitivity or carrying the HLA-B*5801 allele. febuxostat 29-39 major histocompatibility complex, class I, B Homo sapiens 160-165 26216382-8 2015 Mean AUC sUA1-8 was 514.0 +- 225.71 versus 708.0 +- 234.42 mgxh/dl (P < 0.0001) in favor of febuxostat. febuxostat 95-105 SUMO1 activating enzyme subunit 1 Homo sapiens 9-13 26036690-9 2015 Febuxostat also exhibited significant anti-inflammatory (decreased expression of NF-kappaBp65, IKK-beta and TNF-alpha) and anti-apoptotic effect (increased Bcl-2 expression and decreased Bax and caspase-3 expression and TUNEL positivity). febuxostat 0-10 tumor necrosis factor Rattus norvegicus 108-117 26036690-9 2015 Febuxostat also exhibited significant anti-inflammatory (decreased expression of NF-kappaBp65, IKK-beta and TNF-alpha) and anti-apoptotic effect (increased Bcl-2 expression and decreased Bax and caspase-3 expression and TUNEL positivity). febuxostat 0-10 BCL2, apoptosis regulator Rattus norvegicus 156-161 26036690-9 2015 Febuxostat also exhibited significant anti-inflammatory (decreased expression of NF-kappaBp65, IKK-beta and TNF-alpha) and anti-apoptotic effect (increased Bcl-2 expression and decreased Bax and caspase-3 expression and TUNEL positivity). febuxostat 0-10 BCL2 associated X, apoptosis regulator Rattus norvegicus 187-190 26036690-9 2015 Febuxostat also exhibited significant anti-inflammatory (decreased expression of NF-kappaBp65, IKK-beta and TNF-alpha) and anti-apoptotic effect (increased Bcl-2 expression and decreased Bax and caspase-3 expression and TUNEL positivity). febuxostat 0-10 caspase 3 Rattus norvegicus 195-204 26136232-1 2015 BACKGROUND: Febuxostat is a selective inhibitor of xanthine oxidase (XO). febuxostat 12-22 xanthine dehydrogenase Mus musculus 51-67 26136232-16 2015 Febuxostat also protected the mitochondrial structure following myocardial I/R, inhibited H/R-induced ROS generation, stabilized the DeltaPsim, alleviated cytosolic translocation of mitochondrial cytochrome C, inhibited activation of caspase-3 and -9, upregulated antiapoptotic proteins and downregulated proapoptotic proteins. febuxostat 0-10 caspase 3 Mus musculus 234-250 25841777-10 2015 However, inhibition of xanthine oxidoreductase (XOR; febuxostat or allopurinol) abolished the sensitized response to nitrite during hypoxia and acidosis. febuxostat 53-63 xanthine dehydrogenase Homo sapiens 23-46 25999428-0 2015 The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. febuxostat 31-41 xanthine dehydrogenase Mus musculus 4-20 25999428-4 2015 In this study, the XO inhibitor febuxostat was administered to two types of NASH model mice. febuxostat 32-42 xanthine dehydrogenase Mus musculus 19-21 25999428-4 2015 In this study, the XO inhibitor febuxostat was administered to two types of NASH model mice. febuxostat 32-42 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 76-80 25999428-5 2015 Febuxostat exerted a strong protective effect against NASH development induced by a high-fat diet containing trans fatty acid (HFDT). febuxostat 0-10 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 54-58 25999428-9 2015 Taken together, these observations indicate that administration of febuxostat has a protective effect against HFDT-induced NASH development, suggesting the importance of XO in its pathogenesis. febuxostat 67-77 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 123-127 25999428-9 2015 Taken together, these observations indicate that administration of febuxostat has a protective effect against HFDT-induced NASH development, suggesting the importance of XO in its pathogenesis. febuxostat 67-77 xanthine dehydrogenase Mus musculus 170-172 25841777-10 2015 However, inhibition of xanthine oxidoreductase (XOR; febuxostat or allopurinol) abolished the sensitized response to nitrite during hypoxia and acidosis. febuxostat 53-63 xanthine dehydrogenase Homo sapiens 48-51 25744353-4 2015 The recently introduced XOR inhibitor febuxostat, which is a more potent inhibitor than allopurinol, is expected to decrease free radical production more effectively. febuxostat 38-48 xanthine dehydrogenase Mus musculus 24-27 26136193-10 2015 While we did not see an effect of febuxostat on proteasome activity at the end of the study, the pAkt/Akt ratio was improved by febuxostat (0.94 +- 0.09) vs. placebo (0.41 +- 0.05, P < 0.01), suggesting an increase in protein synthesis. febuxostat 128-138 AKT serine/threonine kinase 1 Rattus norvegicus 98-101 25449036-0 2015 The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung. febuxostat 31-41 xanthine dehydrogenase Mus musculus 4-20 25449036-4 2015 Here we test whether a non-nucleoside xanthine oxidase inhibitor, Febuxostat (FBX), can reduce intracellular uric acid levels and inhibit cell death-induced inflammation in two different murine tissue injury models; acid-induced acute lung injury and acetaminophen liver injury. febuxostat 66-76 xanthine dehydrogenase Mus musculus 38-54 25449036-4 2015 Here we test whether a non-nucleoside xanthine oxidase inhibitor, Febuxostat (FBX), can reduce intracellular uric acid levels and inhibit cell death-induced inflammation in two different murine tissue injury models; acid-induced acute lung injury and acetaminophen liver injury. febuxostat 78-81 xanthine dehydrogenase Mus musculus 38-54 26680283-0 2015 Febuxostat Prevents Renal Interstitial Fibrosis by the Activation of BMP-7 Signaling and Inhibition of USAG-1 Expression in Rats. febuxostat 0-10 bone morphogenetic protein 7 Rattus norvegicus 69-74 26680283-0 2015 Febuxostat Prevents Renal Interstitial Fibrosis by the Activation of BMP-7 Signaling and Inhibition of USAG-1 Expression in Rats. febuxostat 0-10 sclerostin domain containing 1 Rattus norvegicus 103-109 26680283-13 2015 CONCLUSION: Febuxostat was able to attenuate RIF caused by UUO, which was associated with the activation of BMP-7-Smad1/5/8 pathway and the inhibition of USAG-1 expression in the kidneys of UUO rats. febuxostat 12-22 bone morphogenetic protein 7 Rattus norvegicus 108-113 26680283-13 2015 CONCLUSION: Febuxostat was able to attenuate RIF caused by UUO, which was associated with the activation of BMP-7-Smad1/5/8 pathway and the inhibition of USAG-1 expression in the kidneys of UUO rats. febuxostat 12-22 SMAD family member 1 Rattus norvegicus 114-121 26680283-13 2015 CONCLUSION: Febuxostat was able to attenuate RIF caused by UUO, which was associated with the activation of BMP-7-Smad1/5/8 pathway and the inhibition of USAG-1 expression in the kidneys of UUO rats. febuxostat 12-22 sclerostin domain containing 1 Rattus norvegicus 154-160 24687403-8 2014 In addition, a newer xanthine oxidoreductase inhibitor, febuxostat, may also be effective in the prevention of calcium stones, as it reduces urinary uric acid excretion. febuxostat 56-66 xanthine dehydrogenase Homo sapiens 21-44 24824603-6 2014 The role of human AO and XO in the metabolism of 6MP was established using the specific inhibitors raloxifene and febuxostat. febuxostat 114-124 aldehyde oxidase 1 Homo sapiens 18-20 24406683-4 2014 To this end, XOR inhibition has been accomplished with application of classic pyrazolopyrimidine-based inhibitors allo/oxypurinol or the newly FDA-approved XOR-specific inhibitor, Uloric (febuxostat). febuxostat 189-199 xanthine dehydrogenase Homo sapiens 13-16 24686534-0 2014 Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. febuxostat 31-41 xanthine dehydrogenase Mus musculus 0-16 24686534-4 2014 Here, we show enhanced XO expression in macrophages in the atherosclerotic plaque and in aortic endothelial cells in ApoE(-/-) mice, and that febuxostat, a highly potent XO inhibitor, suppressed plaque formation, reduced arterial ROS levels and improved endothelial dysfunction in ApoE(-/-) mice without affecting plasma cholesterol levels. febuxostat 142-152 xanthine dehydrogenase Mus musculus 170-172 24686534-4 2014 Here, we show enhanced XO expression in macrophages in the atherosclerotic plaque and in aortic endothelial cells in ApoE(-/-) mice, and that febuxostat, a highly potent XO inhibitor, suppressed plaque formation, reduced arterial ROS levels and improved endothelial dysfunction in ApoE(-/-) mice without affecting plasma cholesterol levels. febuxostat 142-152 apolipoprotein E Mus musculus 281-285 24686534-6 2014 These results demonstrate that in the atherosclerotic plaque, XO-mediated ROS formation is pro-inflammatory and XO-inhibition by febuxostat is a potential therapy for atherosclerosis. febuxostat 129-139 xanthine dehydrogenase Mus musculus 62-64 24152124-7 2014 The change from baseline in eGFR was positive at all time points during febuxostat treatment and the increase of 2.3 (+-5.6) mL/min/1.73 m2 at 6 months was significant (p = 0.0027). febuxostat 72-82 epidermal growth factor receptor Homo sapiens 28-32 24152124-8 2014 Whereas the eGFR slope was negative during allopurinol treatment, it became positive after the switch to febuxostat. febuxostat 105-115 epidermal growth factor receptor Homo sapiens 12-16 24152124-9 2014 The change in eGFR slope before and after febuxostat treatment was significant for all patients (p < 0.01), for male patients (p < 0.05), and for patients with a baseline eGFR of <15 mL/min/1.73 m2 (p < 0.05). febuxostat 42-52 epidermal growth factor receptor Homo sapiens 14-18 24152124-9 2014 The change in eGFR slope before and after febuxostat treatment was significant for all patients (p < 0.01), for male patients (p < 0.05), and for patients with a baseline eGFR of <15 mL/min/1.73 m2 (p < 0.05). febuxostat 42-52 epidermal growth factor receptor Homo sapiens 177-181 24406683-12 2014 Importantly, febuxostat was found to be a very poor inhibitor of human AO (EC50=613 muM) suggesting its usefulness for validating XO-dependent contributions to NO2- reduction in biological systems. febuxostat 13-23 aldehyde oxidase 1 Homo sapiens 71-73 24686534-6 2014 These results demonstrate that in the atherosclerotic plaque, XO-mediated ROS formation is pro-inflammatory and XO-inhibition by febuxostat is a potential therapy for atherosclerosis. febuxostat 129-139 xanthine dehydrogenase Mus musculus 112-114 24406683-11 2014 In contrast to having no effect on XO-catalyzed uric acid production, the AO inhibitor menadione demonstrated potent inhibition of XO-catalyzed NO2- reduction (EC50=60 nM); somewhat similar to the XO-specific inhibitor, febuxostat (EC50=4 nM). febuxostat 220-230 aldehyde oxidase 1 Homo sapiens 74-76 23951137-5 2013 The contribution of XO-generated ROS to the pathogenesis of EAE was assessed by treating EAE mice with a novel XO inhibitor, febuxostat. febuxostat 125-135 xanthine dehydrogenase Mus musculus 20-22 25034030-9 2014 Quantitative analysis showed that hepatic XO and XDH activities were higher in the DM groups, but decreased after treatment with febuxostat. febuxostat 129-139 xanthine dehydrogenase Rattus norvegicus 49-52 23929928-2 2013 Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 14-37 24086554-0 2013 Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. febuxostat 0-10 C-C motif chemokine ligand 2 Homo sapiens 84-89 24086554-0 2013 Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. febuxostat 0-10 dual specificity phosphatase 1 Homo sapiens 105-123 24086554-0 2013 Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. febuxostat 0-10 mitogen-activated protein kinase 8 Homo sapiens 149-152 24086554-5 2013 Here we show that febuxostat suppresses LPS-induced MCP-1 production and mRNA expression via activating MAPK phosphatase-1 (MKP-1) which, in turn, leads to dephosphorylation and inactivation of JNK in macrophages. febuxostat 18-28 C-C motif chemokine ligand 2 Homo sapiens 52-57 24086554-5 2013 Here we show that febuxostat suppresses LPS-induced MCP-1 production and mRNA expression via activating MAPK phosphatase-1 (MKP-1) which, in turn, leads to dephosphorylation and inactivation of JNK in macrophages. febuxostat 18-28 dual specificity phosphatase 1 Homo sapiens 104-122 24086554-5 2013 Here we show that febuxostat suppresses LPS-induced MCP-1 production and mRNA expression via activating MAPK phosphatase-1 (MKP-1) which, in turn, leads to dephosphorylation and inactivation of JNK in macrophages. febuxostat 18-28 dual specificity phosphatase 1 Homo sapiens 124-129 24086554-5 2013 Here we show that febuxostat suppresses LPS-induced MCP-1 production and mRNA expression via activating MAPK phosphatase-1 (MKP-1) which, in turn, leads to dephosphorylation and inactivation of JNK in macrophages. febuxostat 18-28 mitogen-activated protein kinase 8 Homo sapiens 194-197 23913681-4 2013 Plasma uric acid was elevated in obese mice and attenuated by administration of the XOR inhibitor febuxostat. febuxostat 98-108 xanthine dehydrogenase Mus musculus 84-87 23951137-5 2013 The contribution of XO-generated ROS to the pathogenesis of EAE was assessed by treating EAE mice with a novel XO inhibitor, febuxostat. febuxostat 125-135 xanthine dehydrogenase Mus musculus 111-113 23951137-8 2013 Furthermore, prophylactic administration of febuxostat, a XO inhibitor, markedly reduced the clinical signs of EAE. febuxostat 44-54 xanthine dehydrogenase Mus musculus 58-60 23676888-7 2013 Serum creatinine, urinary albumin, cystatin-C and oxidized LDL were also significantly lower in the febuxostat group. febuxostat 100-110 cystatin C Homo sapiens 35-45 24660115-9 2012 Although AG-490 or the combination of AG-490 and febuxostat inhibited signal transducer and activator of transcription-3 activation, apoptosis was unaffected. febuxostat 49-59 signal transducer and activator of transcription 3 Homo sapiens 70-120 22448318-1 2012 Febuxostat, a drug recently approved in the US, European Union and Japan for treatment of gout, inhibits xanthine oxidoreductase (XOR)-mediated generation of uric acid during purine catabolism. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 105-128 22995295-8 2012 Furthermore, febuxostat reduced the induction of endoplasmic reticulum (ER) stress, assessed by GRP-78, ATF4, and CHOP. febuxostat 13-23 heat shock protein family A (Hsp70) member 5 Rattus norvegicus 96-102 22995295-8 2012 Furthermore, febuxostat reduced the induction of endoplasmic reticulum (ER) stress, assessed by GRP-78, ATF4, and CHOP. febuxostat 13-23 activating transcription factor 4 Rattus norvegicus 104-108 22995295-8 2012 Furthermore, febuxostat reduced the induction of endoplasmic reticulum (ER) stress, assessed by GRP-78, ATF4, and CHOP. febuxostat 13-23 DNA-damage inducible transcript 3 Rattus norvegicus 114-118 22242967-1 2012 AIMS: To determine the effect of febuxostat on cytochrome P450 2C8 (CYP2C8) activity using rosiglitazone as a CYP2C8 substrate. febuxostat 33-43 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 47-66 22242967-1 2012 AIMS: To determine the effect of febuxostat on cytochrome P450 2C8 (CYP2C8) activity using rosiglitazone as a CYP2C8 substrate. febuxostat 33-43 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 68-74 23316304-6 2012 Importantly, H(2)S increased ischemic tissue xanthine oxidase activity, hind-limb blood flow, and angiogenesis, which were blunted by the xanthine oxidase inhibitor febuxostat. febuxostat 165-175 xanthine dehydrogenase Mus musculus 45-61 23316304-6 2012 Importantly, H(2)S increased ischemic tissue xanthine oxidase activity, hind-limb blood flow, and angiogenesis, which were blunted by the xanthine oxidase inhibitor febuxostat. febuxostat 165-175 xanthine dehydrogenase Mus musculus 138-154 22448318-1 2012 Febuxostat, a drug recently approved in the US, European Union and Japan for treatment of gout, inhibits xanthine oxidoreductase (XOR)-mediated generation of uric acid during purine catabolism. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 130-133 18995179-0 2008 Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. febuxostat 33-43 xanthine dehydrogenase Mus musculus 0-16 20544512-1 2010 The nonpurine selective xanthine oxidase (XO) inhibitor febuxostat attenuates development of left ventricular (LV) hypertrophy and dysfunction in mice when treatment is initiated within 1 hour of transverse aortic constriction (TAC). febuxostat 56-66 xanthine dehydrogenase Mus musculus 24-40 20544512-1 2010 The nonpurine selective xanthine oxidase (XO) inhibitor febuxostat attenuates development of left ventricular (LV) hypertrophy and dysfunction in mice when treatment is initiated within 1 hour of transverse aortic constriction (TAC). febuxostat 56-66 xanthine dehydrogenase Mus musculus 42-44 20544512-2 2010 This study investigated whether a 7-day delay of treatment with the XO inhibitors febuxostat or allopurinol would reverse TAC-induced changes after onset of heart failure (HF). febuxostat 82-92 xanthine dehydrogenase Mus musculus 68-70 21744407-7 2011 This newly developed methodology has been successfully applied to the syntheses of febuxostat (a xanthine oxidase inhibitor that is effective for the treatment of gout and hyperuricemia), tafamidis (effective for the treatment of TTR amyloid polyneuropathy), and texaline (a natural product having antitubercular activity). febuxostat 83-93 transthyretin Homo sapiens 230-233 21757641-5 2011 Febuxostat, a nonpurine inhibitor of xanthine oxidase (also known as xanthine dehydrogenase or xanthine oxidoreductase) may have advantages over allopurinol and is being tested in a similar protocol, with the eventual goal of determining whether urate-lowering therapy prevents recurrent calcium stones. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 69-91 21757641-5 2011 Febuxostat, a nonpurine inhibitor of xanthine oxidase (also known as xanthine dehydrogenase or xanthine oxidoreductase) may have advantages over allopurinol and is being tested in a similar protocol, with the eventual goal of determining whether urate-lowering therapy prevents recurrent calcium stones. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 95-118 20109996-0 2009 Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 41-63 18995179-6 2008 Febuxostat blunted the TAC-induced increases in nitrotyrosine (indicating reduced myocardial oxidative stress), p-Erk(Thr202/Tyr204), and p-mTOR(Ser2488), with no effect on total Erk or total mTOR. febuxostat 0-10 mitogen-activated protein kinase 1 Mus musculus 114-117 18995179-6 2008 Febuxostat blunted the TAC-induced increases in nitrotyrosine (indicating reduced myocardial oxidative stress), p-Erk(Thr202/Tyr204), and p-mTOR(Ser2488), with no effect on total Erk or total mTOR. febuxostat 0-10 mechanistic target of rapamycin kinase Mus musculus 140-144 18995179-6 2008 Febuxostat blunted the TAC-induced increases in nitrotyrosine (indicating reduced myocardial oxidative stress), p-Erk(Thr202/Tyr204), and p-mTOR(Ser2488), with no effect on total Erk or total mTOR. febuxostat 0-10 mitogen-activated protein kinase 1 Mus musculus 179-182 18995179-6 2008 Febuxostat blunted the TAC-induced increases in nitrotyrosine (indicating reduced myocardial oxidative stress), p-Erk(Thr202/Tyr204), and p-mTOR(Ser2488), with no effect on total Erk or total mTOR. febuxostat 0-10 mechanistic target of rapamycin kinase Mus musculus 192-196 18421623-0 2008 In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. febuxostat 44-54 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 180-195 18421623-7 2008 The UGT 1 and 2 families were involved in the glucuronidation, and several CYPs participated in the metabolism of febuxostat, suggesting that there is little possibility that the blood concentration of febuxostat varies widely even if febuxostat is concomitantly administered with drugs that inhibit CYP or UGT enzyme. febuxostat 114-124 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 75-78 18421623-8 2008 Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP. febuxostat 40-50 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 54-57 15698861-0 2005 Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. febuxostat 15-25 xanthine dehydrogenase Bos taurus 76-98 18421623-8 2008 Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP. febuxostat 80-90 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 54-57 18421623-8 2008 Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP. febuxostat 80-90 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 132-135 18409528-6 2008 The dosage reduction of the new XDH inhibitors, febuxostat and FYX-051, is not necessary in patients with renal insufficiency because renal excretion is not main excretory pathway. febuxostat 48-58 xanthine dehydrogenase Homo sapiens 32-35 18360072-0 2008 Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. febuxostat 100-110 xanthine dehydrogenase Homo sapiens 32-55 18636784-20 2008 Febuxostat is a new xanthine oxidoreductase inhibitor, which is still in clinical trials, but abnormal liver function is the most commonly reported adverse reaction.Even assuming a causal relationship between benzbromarone and hepatotoxicity in the identified cases, benefit-risk assessment based on total exposure to the drug does not support the decision by the drug company to withdraw benzbromarone from the market given the paucity of alternative options. febuxostat 0-10 xanthine dehydrogenase Homo sapiens 20-43 10741381-1 1999 In this study, the hypouricemic efficacy of a novel xanthine oxidase/xanthine dehydrogenase inhibitor, TEI-6720, was compared with that of allopurinol in a hyperuricemic rat model established by feeding the animals oxonate, a uricase inhibitor. febuxostat 103-111 xanthine dehydrogenase Rattus norvegicus 69-91 10823345-5 2000 In contrast, TEI-6720, a newly synthesized xanthine oxidase/xanthine dehydrogenase inhibitor, caused neither pyrimidine metabolism abnormality nor renal impairment in DNFB-sensitized mice. febuxostat 13-21 xanthine dehydrogenase Mus musculus 43-59 12421831-2 2003 TEI-6720 (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid) is an extremely potent inhibitor of xanthine oxidoreductase. febuxostat 0-8 xanthine dehydrogenase Homo sapiens 112-135 12421831-2 2003 TEI-6720 (2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid) is an extremely potent inhibitor of xanthine oxidoreductase. febuxostat 10-74 xanthine dehydrogenase Homo sapiens 112-135 34413161-8 2021 After adding parent compounds to the apical side of induced pluripotent stem cell-derived small intestinal epithelial-like cells, DS, GS, and ES in the basal compartment significantly increased in the presence of lapatinib and febuxostat, suggesting the inhibition of intestinal BCRP. febuxostat 227-237 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 279-283 8243554-5 1993 We evaluated the hypouricemic effect of TEI-6720 on hyperuricemia induced by the uricase inhibitor, potassium oxonate (250 mg/kg s.c., 1 h before the test drugs), and measured the total molarity of both serum allantoin and urate in rats. febuxostat 40-48 urate oxidase Rattus norvegicus 81-88 33031799-8 2020 Furthermore, febuxostat significantly reduced the prostatic content, both in terms of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) messenger ribonucleic acid (mRNA) levels, and of protein levels. febuxostat 13-23 nitric oxide synthase 2 Rattus norvegicus 86-117 33031799-8 2020 Furthermore, febuxostat significantly reduced the prostatic content, both in terms of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) messenger ribonucleic acid (mRNA) levels, and of protein levels. febuxostat 13-23 nitric oxide synthase 2 Rattus norvegicus 119-123 33031799-8 2020 Furthermore, febuxostat significantly reduced the prostatic content, both in terms of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) messenger ribonucleic acid (mRNA) levels, and of protein levels. febuxostat 13-23 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 129-145 33031799-8 2020 Furthermore, febuxostat significantly reduced the prostatic content, both in terms of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) messenger ribonucleic acid (mRNA) levels, and of protein levels. febuxostat 13-23 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 147-152 34407232-7 2021 Both allopurinol and febuxostat reversed the increase in levels of sodium glucose co-transporter (SGLT) 1, SGLT2, and glucose transporter (GLUT) 2 (all P < 0.05). febuxostat 21-31 solute carrier family 5 member 1 Rattus norvegicus 67-105 34407232-7 2021 Both allopurinol and febuxostat reversed the increase in levels of sodium glucose co-transporter (SGLT) 1, SGLT2, and glucose transporter (GLUT) 2 (all P < 0.05). febuxostat 21-31 solute carrier family 5 member 2 Rattus norvegicus 107-112 34407232-7 2021 Both allopurinol and febuxostat reversed the increase in levels of sodium glucose co-transporter (SGLT) 1, SGLT2, and glucose transporter (GLUT) 2 (all P < 0.05). febuxostat 21-31 solute carrier family 2 member 2 Rattus norvegicus 118-146 33773042-6 2021 The calibration curves of diflunisal, lesinurad, and febuxostat were linear over concentration ranges of 50.0-500.0, 50.0-700.0, and 20.0-700.0 ng mL-1 , respectively. febuxostat 53-63 L1 cell adhesion molecule Mus musculus 147-151 34726078-0 2021 Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat. febuxostat 116-126 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 73-105 34726078-3 2021 Febuxostat, a urate-lowering drug, inhibits BCRP. febuxostat 0-10 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 44-48 34726078-11 2021 CONCLUSION AND RELEVANCE: Our findings suggest that patients being treated with intravenous MTX who concomitantly use febuxostat may be at an increased risk of hematologic events, presumably due to BCRP-mediated drug-drug interaction. febuxostat 118-128 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 198-202 34281235-3 2021 In our study, we investigated the effects of venlafaxine (antidepressant, serotonin-norepinephrine reuptake inhibitor), risperidone (atypical antipsychotic) and febuxostat (gout medication, xanthine oxidase inhibitor) in the cuprizone mouse model of acute demyelination, hypothesizing an antagonistic effect on TRPA1 calcium channels. febuxostat 161-171 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 311-316 34538151-0 2021 Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-kappaB. febuxostat 0-10 xanthine dehydrogenase Mus musculus 28-44 34538151-0 2021 Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-kappaB. febuxostat 0-10 caspase 3 Mus musculus 112-121 34538151-0 2021 Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-kappaB. febuxostat 0-10 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 144-153 34538151-1 2021 Febuxostat (FBX), a selective inhibitor of xanthine oxidase, has several biological properties such as antioxidant, anti-inflammatory and anti-apoptosis activities. febuxostat 0-10 xanthine dehydrogenase Mus musculus 43-59 34538151-1 2021 Febuxostat (FBX), a selective inhibitor of xanthine oxidase, has several biological properties such as antioxidant, anti-inflammatory and anti-apoptosis activities. febuxostat 12-15 xanthine dehydrogenase Mus musculus 43-59 34488603-2 2022 Febuxostat (FBX), as an inhibitor of xanthine oxidase, has anti-inflammatory, antioxidant, and anti-apoptosis properties. febuxostat 0-10 xanthine dehydrogenase Mus musculus 37-53 34488603-2 2022 Febuxostat (FBX), as an inhibitor of xanthine oxidase, has anti-inflammatory, antioxidant, and anti-apoptosis properties. febuxostat 12-15 xanthine dehydrogenase Mus musculus 37-53 34281235-11 2021 The agonistic activity of febuxostat can be of potential use for discovering novel TRPA1 ligands. febuxostat 26-36 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 83-88 35419185-0 2022 The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia. febuxostat 15-25 lipocalin 2 Homo sapiens 35-39 34278932-11 2021 Furthermore, mice in group TB showed significant loss of body weight and muscle weight in which XO activity, 8-OHdG, and expression of IL-6 were significantly increased compared to those in group C. Febuxostat administration not only significantly improved the body weight and muscleweight, but also reduced markers of oxidative stress and pro-inflammatory cytokines. febuxostat 199-209 interleukin 6 Mus musculus 135-139 34084553-6 2021 High sensitivity was attained for the two drugs with limits of quantitations (LODs) down to 0.41 and 5.51 ng ml-1 in the first method and 0.25 and 3.32 ng ml-1 in the second method for FEB and IBU, respectively. febuxostat 185-188 interleukin 17F Homo sapiens 155-159 35419185-1 2022 Retrospective analysis of the effects of febuxostat on urine neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in patients with hyperuricemia was performed. febuxostat 41-51 lipocalin 2 Homo sapiens 61-103 35419185-1 2022 Retrospective analysis of the effects of febuxostat on urine neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in patients with hyperuricemia was performed. febuxostat 41-51 lipocalin 2 Homo sapiens 105-109 35419185-1 2022 Retrospective analysis of the effects of febuxostat on urine neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in patients with hyperuricemia was performed. febuxostat 41-51 hepatitis A virus cellular receptor 1 Homo sapiens 115-139 35419185-1 2022 Retrospective analysis of the effects of febuxostat on urine neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in patients with hyperuricemia was performed. febuxostat 41-51 hepatitis A virus cellular receptor 1 Homo sapiens 141-146 35215344-10 2022 FEB pre-treatment reduced MDA, TNF-, and IL-1 while increasing SOD, GSH, and NOx. febuxostat 0-3 tumor necrosis factor Rattus norvegicus 31-34 35088420-0 2022 Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug-Drug Interactions with Rivaroxaban. febuxostat 0-10 solute carrier family 22 member 8 Homo sapiens 78-105 35088420-2 2022 It was recently reported that febuxostat inhibited organic anion transporter 3 (OAT3)-mediated uptake of enalaprilat. febuxostat 30-40 solute carrier family 22 member 8 Homo sapiens 51-78 35088420-2 2022 It was recently reported that febuxostat inhibited organic anion transporter 3 (OAT3)-mediated uptake of enalaprilat. febuxostat 30-40 solute carrier family 22 member 8 Homo sapiens 80-84 35088420-4 2022 Our transporter inhibition assays confirmed the potent noncompetitive and competitive inhibition of OAT3-mediated estrone-3-sulfate transport by febuxostat and febuxostat AG with corresponding apparent Ki values of 0.55 muM and 6.11 muM respectively. febuxostat 145-155 solute carrier family 22 member 8 Homo sapiens 100-104 35088420-6 2022 Taken together, our results suggested that the concomitant usage of febuxostat with rivaroxaban may potentially culminate in a clinically-significant drug-drug interaction and result in an increased risk of bleeding as a result of its OAT3 inhibition. febuxostat 68-78 solute carrier family 22 member 8 Homo sapiens 235-239 35260678-7 2022 The interaction between febuxostat treatment and presence of proteinuria in terms of eGFR slope was significant (P for interaction = 0.019). febuxostat 24-34 epidermal growth factor receptor Homo sapiens 85-89 35215344-11 2022 FEB also significantly increased TRPC1 and decreased CHOP in parotid gland tissue. febuxostat 0-3 transient receptor potential cation channel, subfamily C, member 1 Rattus norvegicus 33-38 35215344-11 2022 FEB also significantly increased TRPC1 and decreased CHOP in parotid gland tissue. febuxostat 0-3 DNA-damage inducible transcript 3 Rattus norvegicus 53-57 35215344-12 2022 In conclusion, FEB pre-treatment reduced 5-FU-induced parotid salivary gland damage not only through its powerful anti-inflammatory and antioxidant effects, but also through its effect on the TRPC1/CHOP signalling pathway. febuxostat 15-18 transient receptor potential cation channel, subfamily C, member 1 Rattus norvegicus 192-197 35215344-12 2022 In conclusion, FEB pre-treatment reduced 5-FU-induced parotid salivary gland damage not only through its powerful anti-inflammatory and antioxidant effects, but also through its effect on the TRPC1/CHOP signalling pathway. febuxostat 15-18 DNA-damage inducible transcript 3 Rattus norvegicus 198-202 34030558-0 2021 Nephroprotective effects of febuxostat and/or mirtazapine against gentamicin-induced nephrotoxicity through modulation of ERK 1/2, NF-kappaB and MCP1. febuxostat 28-38 mitogen-activated protein kinase 3 Homo sapiens 122-129 35089941-11 2022 Febuxostat yielded the highest utility, but also the highest costs ($4,385 vs. $4,063 for allopurinol), resulting in an ICER of $25,173 when compared to allopurinol. febuxostat 0-10 cAMP responsive element modulator Homo sapiens 120-124 33443645-0 2021 Febuxostat Inhibits MPP+-Induced Inflammatory Response Through Inhibiting the JNK/NF-kappaB Pathway in Astrocytes. febuxostat 0-10 mitogen-activated protein kinase 8 Rattus norvegicus 78-81 33443645-11 2021 Thirdly, febuxostat alleviated MPP+-induced inflammatory responses in astrocytes by reducing the expressions of IL-8, IL-1beta, TNF-alpha, GFAP, MMP-2, and MMP-9. febuxostat 9-19 interleukin 1 alpha Rattus norvegicus 118-126 33443645-11 2021 Thirdly, febuxostat alleviated MPP+-induced inflammatory responses in astrocytes by reducing the expressions of IL-8, IL-1beta, TNF-alpha, GFAP, MMP-2, and MMP-9. febuxostat 9-19 tumor necrosis factor Rattus norvegicus 128-137 33443645-11 2021 Thirdly, febuxostat alleviated MPP+-induced inflammatory responses in astrocytes by reducing the expressions of IL-8, IL-1beta, TNF-alpha, GFAP, MMP-2, and MMP-9. febuxostat 9-19 glial fibrillary acidic protein Rattus norvegicus 139-143 33443645-11 2021 Thirdly, febuxostat alleviated MPP+-induced inflammatory responses in astrocytes by reducing the expressions of IL-8, IL-1beta, TNF-alpha, GFAP, MMP-2, and MMP-9. febuxostat 9-19 matrix metallopeptidase 2 Rattus norvegicus 145-150 33443645-11 2021 Thirdly, febuxostat alleviated MPP+-induced inflammatory responses in astrocytes by reducing the expressions of IL-8, IL-1beta, TNF-alpha, GFAP, MMP-2, and MMP-9. febuxostat 9-19 matrix metallopeptidase 9 Rattus norvegicus 156-161 33443645-12 2021 Importantly, we found that febuxostat mitigated activation of the JNK/NF-kappaB signaling pathway by inhibiting the phosphorylation of JNK and nuclear translocation of NF-kappaB p65.Febuxostat attenuated MPP+-induced inflammatory response by suppressing the JNK/NF-kappaB signaling pathway in astrocytes. febuxostat 27-37 mitogen-activated protein kinase 8 Rattus norvegicus 66-69 33443645-12 2021 Importantly, we found that febuxostat mitigated activation of the JNK/NF-kappaB signaling pathway by inhibiting the phosphorylation of JNK and nuclear translocation of NF-kappaB p65.Febuxostat attenuated MPP+-induced inflammatory response by suppressing the JNK/NF-kappaB signaling pathway in astrocytes. febuxostat 27-37 mitogen-activated protein kinase 8 Rattus norvegicus 135-138 33443645-12 2021 Importantly, we found that febuxostat mitigated activation of the JNK/NF-kappaB signaling pathway by inhibiting the phosphorylation of JNK and nuclear translocation of NF-kappaB p65.Febuxostat attenuated MPP+-induced inflammatory response by suppressing the JNK/NF-kappaB signaling pathway in astrocytes. febuxostat 27-37 mitogen-activated protein kinase 8 Rattus norvegicus 135-138 33443645-12 2021 Importantly, we found that febuxostat mitigated activation of the JNK/NF-kappaB signaling pathway by inhibiting the phosphorylation of JNK and nuclear translocation of NF-kappaB p65.Febuxostat attenuated MPP+-induced inflammatory response by suppressing the JNK/NF-kappaB signaling pathway in astrocytes. febuxostat 182-192 mitogen-activated protein kinase 8 Rattus norvegicus 66-69 34030558-0 2021 Nephroprotective effects of febuxostat and/or mirtazapine against gentamicin-induced nephrotoxicity through modulation of ERK 1/2, NF-kappaB and MCP1. febuxostat 28-38 nuclear factor kappa B subunit 1 Homo sapiens 131-140 34030558-0 2021 Nephroprotective effects of febuxostat and/or mirtazapine against gentamicin-induced nephrotoxicity through modulation of ERK 1/2, NF-kappaB and MCP1. febuxostat 28-38 C-C motif chemokine ligand 2 Homo sapiens 145-149 34030558-6 2021 RESULTS: Febuxostat and mirtazapine significantly (p<0.05) alleviated biochemical and histopathological alterations that were induced by gentamicin and for the first time, significantly decreased the renal levels of ERK1/2 and MCP-1. febuxostat 9-19 mitogen-activated protein kinase 3 Homo sapiens 216-222 34030558-6 2021 RESULTS: Febuxostat and mirtazapine significantly (p<0.05) alleviated biochemical and histopathological alterations that were induced by gentamicin and for the first time, significantly decreased the renal levels of ERK1/2 and MCP-1. febuxostat 9-19 C-C motif chemokine ligand 2 Homo sapiens 227-232 34052736-7 2021 Docking of compounds 5a, 14b, 17, 19c, 19e and 21b with the active sites of XO and COX-2 isozymes demonstrated superior binding profile compared with the reported ligands (febuxostat and celecoxib, respectively). febuxostat 172-182 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 33790363-3 2021 These transporters are inhibited by some hypouricemic agents; OATs by probenecid and benzbromarone, ABCG2 by febuxostat and benzbromarone. febuxostat 109-119 ATP binding cassette subfamily G member 2 Rattus norvegicus 100-105 33722946-2 2021 Gout is the most common inflammatory arthritis1, historically poorly managed, and is arguably the only one of the inflammatory arthritides that is curable with appropriate urate-lowering therapy (ULT)2 Whereas febuxostat has been shown to be a more effective ULT3, allopurinol has been the cornerstone of treatment for decades; however, allopurinol is problematic in the elderly, those with renal impairment, and those who carry the HLA-B*5801 antigen who are primarily of Asian origin. febuxostat 210-220 major histocompatibility complex, class I, B Homo sapiens 433-438